AI developer Cortechs.ai has received approval from Health Canada for its medical imaging analysis software suite.
Cortechs.ai’s suite includes NeuroQuant and NeuroQuant MS, with automated brain segmentation and volumetric analysis, which are designed to assist in the early detection and monitoring of neurodegenerative diseases such as Alzheimer’s and multiple sclerosis, as well as the quantitative imaging analysis tool NeuroQuant Brain Tumor for evaluating brain tumor progression. Additionally, the suite offers OnQ Prostate for MRI assessment of prostate cancer.
The NeuroQuant 5.0 software update was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) last September.
